The MLX90620 FIRray sensing device from Melexis, utilizes the company’s innovative non-contact temperature measurement technology to create a highly cost-effective thermography solution. Covering a -20°C to 300°C temperature range, this 16 x 4 element far infrared (FIR) thermopile sensor array produces a map of heat values for the target area in real time, avoiding the need to scan the area with a single point sensor or to use of an expensive microbolometer device.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/melexis/53790
http://onlinewealthpartner.com/mlsp-3 MLM
Lead System Pro - MLSP. Social proof goes along way and you will get
social proof on exactly how MLM Lead System Pro - MLSP can help you in
your network marketing business so you no longer have to chase around
your warm market. Discover how you can generate leads every single day,
and get the training you deserve to build a successful mlm business.
Contact Bill or Michelle at 214 662 2841.
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Prem Rabindranauth, MD, a heart surgeon at Gundersen Lutheran Health System in La Crosse, Wis., is using an exciting technique, called minimally invasive coronary surgery (MICS), to perform heart bypass surgery. To perform MICS, a very small three-inch cut is made between the ribs instead of the long cut through the breast bone that is needed with traditional open heart surgery. This means less pain and blood loss, fewer risks for problems, shorter hospital stays and quicker healing time.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gundluth/49124/
Merry Christmas! Each year our yard display becomes bigger and bigger. We made the front page of the newspaper last year and were highlighted on the television web sites. Last year over 1028 children visited with Santa and Mrs. Clause and everyone received candy canes. This is another Bear Cave System production, and the Celebration of the Christmas Holiday with lights and yard displays. May you enjoy the show! Blessings to all! Happy holidays......Amen
The joy of sharing the wonders of the holidays can be no more stated than a Special Lights of Christmas Yard Display. May you enjoy peeking at ours.
Your also invited to visit the Bear Cave System web sites...In any go bar, or in any search engine: Simply type in pabear48
Family safe and mind interesting...Have fun exploring!
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Today, Google revealed that the next version of its mobile operating system, Android, is named after the world’s favorite cookie – Android OREO. Historically, Google has named each successive Android release after sweet treats like Eclair, Ice Cream Sandwich and most recently, Nougat. The Android OREO release marks a global collaboration between the OREO brand and Google, which kicks off with the debut of the Android OREO superhero — a new character who personifies the powers of this iconic duo and the features of the new operating system.
Poised to be a pop-culture icon, the Android OREO superhero channels the playfulness of OREO and intelligence of Android to spread joy throughout the world. And, like all iconic superheroes, the Android OREO superhero originated from a wondrous, and unique, moment in time: the 2017 solar eclipse. To see Android OREO's story, visit: https://www.youtube.com/watch?v=twZggnNbFqo.
To view the multimedia release go to:
https://www.multivu.com/players/English/8162351-oreo-google-reveal-android-oreo-operating-system-superhero/
More than 80,000 healthcare workers and their communities from across the country and around the world joined together in the Medline Pink Glove Dance for breast cancer online video competition. After a hard-fought dance battle, the online votes are in and Medline is pleased to name Geisinger Health System, Danville, Pa., as the winner. As a result, $25,000 will be donated to their charity of choice, the American Cancer Society, providing free transportation for treatment to central Pennsylvania breast cancer patients in need. Additionally, Medline and participating hospitals will donate another $1 million to the National Breast Cancer Foundation and various local breast cancer charities nationwide. More than $2.2 million has been donated through the campaign and Medline Foundation since 2005.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64450-medline-pink-glove-dance-video-competition-winners-breast-cancer-education
The Medium Extended Air Defense System (MEADS) successfully completed its first flight test today at White Sands Missile Range, N.M.
The PAC-3 Missile Segment Enhancement (MSE) MEADS Certified Missile Round was employed during the test along with the MEADS lightweight launcher and battle manager.
The test demonstrated an unprecedented over-the-shoulder launch of the MSE missile against a simulated target attacking from behind. It required a unique sideways maneuver, demonstrating a 360-degree capability. The missile executed a planned self-destruct sequence at the end of the mission after successfully engaging the simulated threat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53248-meads-conducts-successful-first-flight-test-white-sands-missile-range
